Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis

Investigational New Drugs

Volumn 27, Issue 6, 2009, Pages 543-551

  Brüning, Ansgar ^a   Burger, Petra ^a   Vogel, Marianne ^a   Rahmeh, Martina ^a   Friese, Klaus ^a   Lenhard, Miriam ^a   Burges, Alexander ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bortezomib; Cell cycle; Ovarian cancer; Taxol; TRAIL

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BORTEZOMIB; CARBOPLATIN; CYCLIN DEPENDENT KINASE 1; DEATH RECEPTOR 5; HEAT SHOCK PROTEIN; PACLITAXEL; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; EXPLANT; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CDC2 PROTEIN KINASE; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN ARRAY ANALYSIS; PYRAZINES; STRESS, PHYSIOLOGICAL; TIME FACTORS; UP-REGULATION;

EID: 70450243091     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9206-4     Document Type: Article

References (28)

1. K Tobinai 2007 Proteasome inhibitor, bortezomib, for myeloma and lymphoma Int J Clin Oncol 12 318 326 10.1007/s10147-007-0695-5 1:CAS:528: DC%2BD2sXhtFGgsb%2FP 17929113 (Pubitemid 47573415)
2. AM Davies PN Lara Jr PC Mack DR Gandara 2007 Incorporating bortezomib into the treatment of lung cancer Clin Cancer Res 13 4647 4651 10.1158/1078-0432.CCR-07-0334 (Pubitemid 47219741)
3. P Schmid D Kühnhardt P Kiewe S Lehenbauer-Dehm W Schippinger R Greil W Lange J Preiss N Niederle P Brossart W Freier S Kümmel H Van de Velde A Regierer K Possinger 2008 A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines Ann Oncol 19 871 876 10.1093/annonc/mdm569 1:STN:280: DC%2BD1c3nvFWgtw%3D%3D 18209010 (Pubitemid 351627300)
4. C Aghajanian DS Dizon P Sabbatini JJ Raizer J Dupont DR Spriggs 2005 Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer J Clin Oncol 23 5943 5949 10.1200/JCO.2005.16.006 1:CAS:528:DC%2BD2MXhtVKgtbzE 16135465 (Pubitemid 46300211)
5. PT Ramirez CN Landen Jr RL Coleman MR Milam C Levenback TA Johnston DM Gershenson 2008 Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer Gynecol Oncol 108 68 71 10.1016/j.ygyno.2007.08.071 1:CAS:528:DC%2BD1cXhtlSgsg%3D%3D 17905421 (Pubitemid 350299423)
6. DP Ryan BH O'Neil JG Supko CM Rocha Lima EC Dees LJ Appleman J Clark P Fidias RZ Orlowski O Kashala JP Eder JC Cusack Jr 2006 A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors Cancer 107 2688 2697 10.1002/cncr.22280 1:CAS:528:DC%2BD28XhtlCmu7nI 17075878 (Pubitemid 44845625)
7. GK Dy JP Thomas G Wilding L Bruzek S Mandrekar C Erlichman D Alberti K Binger HC Pitot SR Alberts LJ Hanson R Marnocha K Tutsch SH Kaufmann AA Adjei 2005 A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer Clin Cancer Res 11 3410 3416 10.1158/1078-0432.CCR-04-2068 1:CAS:528: DC%2BD2MXjslOqt7g%3D 15867242 (Pubitemid 40627894)
8. A Milano RV Iaffaioli F Caponigro 2007 The proteasome: a worthwhile target for the treatment of solid tumours Eur J Cancer 43 1125 1133 10.1016/j.ejca.2007.01.038 1:CAS:528:DC%2BD2sXksFWktbo%3D 17379504 (Pubitemid 46592015)
9. GH Eltabbakh CS Awtrey 2001 Current treatment for ovarian cancer Expert Opin Pharmacother 2 109 124 10.1517/14656566.2.1.109 1:CAS:528: DC%2BD3MXitF2guro%3D 11336573 (Pubitemid 32427718)
10. Z Jin WS El-Deiry 2005 Overview of cell death signaling pathways Cancer Biol Ther 4 139 163 1:CAS:528:DC%2BD28XhvFKgs7k%3D 15725726
11. B Vogelstein D Lane AJ Levine 2000 Surfing the p53 network Nature 408 307 310 10.1038/35042675 1:CAS:528:DC%2BD3cXosVemtrY%3D 11099028
12. C Van Waes 2007 Nuclear factor-kappaB in development, prevention, and therapy of cancer Clin Cancer Res 13 1076 1082 10.1158/1078-0432.CCR-06-2221 17317814 (Pubitemid 46424045)
13. T Abdollahi 2004 Potential for TRAIL as a therapeutic agent in ovarian cancer Vitam Horm 67 347 364 10.1016/S0083-6729(04)67018-X 1:CAS:528: DC%2BD2cXltlKgtLg%3D 15110185 (Pubitemid 39753670)
14. MA Jordan K Kamath 2007 How do microtubule-targeted drugs work? An overview Curr Cancer Drug Targets 7 730 742 10.2174/156800907783220417 1:CAS:528:DC%2BD1cXhsFOnsbg%3D 18220533
15. A Mani EP Gelmann 2005 The ubiquitin-proteasome pathway and its role in cancer J Clin Oncol 23 4776 4789 10.1200/JCO.2005.05.081 1:CAS:528: DC%2BD2MXotFars7o%3D 16034054 (Pubitemid 46224082)
16. J Zimmermann D Erdmann I Lalande R Grossenbacher M Noorani P Fürst 2000 Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1 Oncogene 19 2913 2920 10.1038/sj.onc.1203606 1:CAS:528:DC%2BD3cXksF2ns78%3D 10871842
17. EJ Benz Jr DG Nathan RK Amaravadi NN Danial 2007 Targeting the cell death-survival equation Clin Cancer Res 13 7250 7253 10.1158/1078-0432.CCR-07- 2221 18094404
18. A Fribley CY Wang 2006 Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress Cancer Biol Ther 5 745 748 1:CAS:528:DC%2BD28XhtVOju77J 16861900
19. E Saulle A Petronelli L Pasquini E Petrucci G Mariani M Biffoni G Ferretti G Scambia P Benedetti-Panici F Cognetti R Humphreys C Peschle U Testa 2007 Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis Apoptosis 12 635 655 10.1007/s10495-006-0025-9 1:CAS:528: DC%2BD2sXivVShtLg%3D 17252198 (Pubitemid 46411475)
20. R Koschny H Walczak TM Ganten 2007 The promise of TRAIL-potential and risks of a novel anticancer therapy J Mol Med 85 923 935 10.1007/s00109-007- 0194-1 1:CAS:528:DC%2BD2sXptFehtLc%3D 17437073 (Pubitemid 47282789)
21. MP Fanucchi FV Fossella R Belt R Natale P Fidias DP Carbone R Govindan LE Raez F Robert M Ribeiro W Akerley K Kelly SA Limentani J Crawford HJ Reimers R Axelrod O Kashala S Sheng JH Schiller 2006 Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer J Clin Oncol 24 5025 5033 10.1200/JCO.2006.06.1853 1:CAS:528:DC%2BD28Xht1GnurzE 17075122 (Pubitemid 46631406)
22. J Pines CL Rieder 2001 Re-staging mitosis: a contemporary view of mitotic progression Nat Cell Biol 3 E3 E6 10.1038/35050676 1:CAS:528: DC%2BD3MXkslGltQ%3D%3D 11146636 (Pubitemid 32114814)
23. T Bashir M Pagano 2005 Cdk1: the dominant sibling of Cdk2 Nat Cell Biol 7 779 781 10.1038/ncb0805-779 1:CAS:528:DC%2BD2MXmvVCltbg%3D 16056272 (Pubitemid 41079049)
24. J Yu S Tiwari P Steiner L Zhang 2003 Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells Cancer Biol Ther 2 694 649 1:CAS:528: DC%2BD2cXhvVCjsbo%3D 14688479
25. AM Fribley B Evenchik Q Zeng BK Park JY Guan H Zhang TJ Hale MS Soengas RJ Kaufman CY Wang 2006 Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa J Biol Chem 281 31440 31447 10.1074/jbc.M604356200 1:CAS:528:DC%2BD28XhtVOrtr7F 16928686 (Pubitemid 46041408)
26. S Laframboise W Chapman J McLaughlin IL Andrulis 2000 p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance Cancer J 6 302 308 1:STN:280:DC%2BD3M7jsVGhug%3D%3D 11079169
27. M Fraser B Leung A Jahani-Asl X Yan WE Thompson BK Tsang 2003 Chemoresistance in human ovarian cancer: the role of apoptotic regulators Reprod Biol Endocrinol 1 66 10.1186/1477-7827-1-66 14609433 (Pubitemid 39130459)
28. N Colombo T Van Gorp G Parma F Amant G Gatta C Sessa I Vergote 2006 Ovarian cancer Crit Rev Oncol Hematol 60 159 179 10.1016/j.critrevonc.2006.03. 004 17018256 (Pubitemid 44636248)